Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.32 (market cap $75.52B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is the larger of the two by market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.4% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MDLZ | |
|---|---|---|
Market Cap | $39.89B | $75.52B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $70.75 |
52-Week Low | $278.09 | $51.51 |
Enterprise Value | $38.15B | $95.62B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Mondelez International (MDLZ) trades at $58.83, up 0.91% today, with a bearish technical signal but strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $0.67. Revenue grew to $38.54B in 2025, though net income margin compressed to 6.64%. Recent news highlights innovation in packaging and new product launches, alongside a stable dividend of $0.50 per share.
The outlook remains positive with a consensus price target of $68.33, implying 16% upside. Key opportunities include resilient snacking demand and strategic innovations, while risks involve margin pressure from input costs and competitive intensity. Institutional sentiment is bullish, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
